At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
LY2140023 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Impact of Activated Charcoal on the Absorption of LY2140023 in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating LY2140023 and Aqueous activated charcoal for Healthy Volunteer Study. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The study will evaluate the effect of activated charcoal on absorption of LY2140023. The study involves a single dose of 80 milligrams (mg) LY2140023 taken as 1 tablet by mouth 2 times during study (once with activated charcoal, once without activated charcoal). This study will last approximately 16 days, not including screening. Screening is required within 28 days prior to study entry.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteer Study
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 2012
Enrollment StartJun 2012
Primary CompletionSep 2012
TodayJul 2026
First PostedMay 31, 2012
Enrollment StartJun 1, 2012
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 14.1 years ago
Interventions
LY2140023drug
Aqueous activated charcoaldrug